All previous attempts for the definition aimed at separating HER2‐positive from HER2‐negative BC for therapeutic and prognostic purposes,5, 6, 27, 32, 33 as patients with tumours that show low or moderate levels of HER2 protein expression without confirmed gene amplification are currently not candidates for anti‐HER2 agents.9 Here, ERBB2 is linked to breast cancer.